Cutaneous T Cell Lymphoma: What Patients and Families Should Know

Mycosis fungoides is the most common form of CTCL. It often begins as flat, scaly, itchy patches that can look like eczema or psoriasis. Over time it can progress to raised plaques and, in some patients, tumors or widespread skin redness.

Sézary syndrome is an advanced, whole body variant marked by intense redness across most of the skin (erythroderma) along with cancerous cells in the blood.

• Patches: flat, discolored, often itchy areas.
• Plaques: thicker, raised, scaly areas.
• Tumors: raised nodules that may break down or ulcerate.
• Erythroderma: redness and scaling covering most of the body, often with severe itch.

Early CTCL can look almost identical to common skin conditions. Many patients are treated for eczema, psoriasis, or dermatitis for years before the correct diagnosis is made. In the international PROCLIPI study, a diagnostic delay between first symptom and diagnosis occurred in about 85.6 percent of patients, with a median delay of 36 months.

There is no single test. Doctors combine a skin examination with one or more skin biopsies, specialized staining of the tissue, tests for clonal T cells, and, when the blood may be involved, blood flow cytometry. Doctors then assign a stage using the TNMB system (tumor, node, metastasis, blood).

Early stage CTCL is frequently managed with skin directed treatments such as topical steroids, light therapy, and targeted creams, and outcomes for the earliest stages are often favorable. Advanced disease may require systemic medicines, antibody therapies, radiation, or stem cell transplant, and the outlook is more guarded. Your care team can explain your individual prognosis.